https://www.selleckchem.com/pr....oducts/glutathione.h
Interstitial lung disease (ILD) represents a severe clinical manifestation of systemic immune dysregulation in patients with common variable immunodeficiency (CVID). Its treatment often requires systemic immunosuppression beyond corticosteroids. To assess the safety and efficacy of abatacept in patients with CVID and ILD. Ten patients with confirmed diagnosis ofCVIDand ILD were included in a single-center, prospective, open-label, nonrandomized trial. Abatacept was administered subcutaneously at a dose of 125 mg/wk for 12 months. Ab
Like
Comment
Share
